TY - JOUR
T1 - Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma
AU - Dursun, Furkan
AU - Elshabrawy, Ahmed
AU - Wang, Hanzhang
AU - Rodriguez, Ronald
AU - Liss, Michael A.
AU - Kaushik, Dharam
AU - Gelfond, Jonathan
AU - Mansour, Ahmed M.
N1 - Publisher Copyright:
© 2022, The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
PY - 2022/6
Y1 - 2022/6
N2 - Background: A recently reported phase III randomized trial comparing open and minimally invasive hysterectomy showed significantly higher rates of local recurrence after minimally invasive surgery (MIS) for cervical cancer. This raised concerns regarding patterns of recurrences and survival after MIS in general. This study aims to determine the effect of MIS on all-cause mortality among patients undergoing radical nephrectomy for Stage I and II renal cell carcinoma (RCC). Methods: We utilized the National Cancer Database to identify patients diagnosed with clinical stage I–II RCCs between 2010 and 2013. Patients for whom a laparoscopic or robotic radical nephrectomy was attempted were compared to patients who underwent open radical nephrectomy (ORN). Adjusted regression models with inverse probability propensity score weighting (IPW) were utilized to identify independent predictors of receiving MIS. All-cause mortality rates were compared using IPW survival functions and log-rank tests. Adjusted Cox proportional hazard models were fitted to determine independent predictors of OS. Results: 27,642 patients were identified; 11,524 (41.7%) had MIS, while 16,118 (58.3%) had ORN. Kaplan–Meier survival curves in the IPW cohort showed significant OS advantage for patients who underwent MIS (p < 0.001). Furthermore, length of hospital stays (3 vs. 4 days), 30 day readmission rates (2.4 vs. 2.87%), 30 day (0.53 vs. 0.96%) and 90 day mortality rates (1.04 vs. 1.77%) were significantly higher in the ORN group (p < 0.001). Conclusions: MIS was associated with better OS outcomes compared to ORN for stage I and II RCC. In addition, MIS had lower post-operative readmission, 30- and 90 day mortality rates.
AB - Background: A recently reported phase III randomized trial comparing open and minimally invasive hysterectomy showed significantly higher rates of local recurrence after minimally invasive surgery (MIS) for cervical cancer. This raised concerns regarding patterns of recurrences and survival after MIS in general. This study aims to determine the effect of MIS on all-cause mortality among patients undergoing radical nephrectomy for Stage I and II renal cell carcinoma (RCC). Methods: We utilized the National Cancer Database to identify patients diagnosed with clinical stage I–II RCCs between 2010 and 2013. Patients for whom a laparoscopic or robotic radical nephrectomy was attempted were compared to patients who underwent open radical nephrectomy (ORN). Adjusted regression models with inverse probability propensity score weighting (IPW) were utilized to identify independent predictors of receiving MIS. All-cause mortality rates were compared using IPW survival functions and log-rank tests. Adjusted Cox proportional hazard models were fitted to determine independent predictors of OS. Results: 27,642 patients were identified; 11,524 (41.7%) had MIS, while 16,118 (58.3%) had ORN. Kaplan–Meier survival curves in the IPW cohort showed significant OS advantage for patients who underwent MIS (p < 0.001). Furthermore, length of hospital stays (3 vs. 4 days), 30 day readmission rates (2.4 vs. 2.87%), 30 day (0.53 vs. 0.96%) and 90 day mortality rates (1.04 vs. 1.77%) were significantly higher in the ORN group (p < 0.001). Conclusions: MIS was associated with better OS outcomes compared to ORN for stage I and II RCC. In addition, MIS had lower post-operative readmission, 30- and 90 day mortality rates.
KW - Minimally invasive surgery
KW - Open surgery
KW - Radical Nephrectomy
KW - Renal Cell Carcinoma
UR - https://www.scopus.com/pages/publications/85126835960
UR - https://www.scopus.com/pages/publications/85126835960#tab=citedBy
U2 - 10.1007/s10147-022-02153-5
DO - 10.1007/s10147-022-02153-5
M3 - Article
C2 - 35319076
AN - SCOPUS:85126835960
SN - 1341-9625
VL - 27
SP - 1068
EP - 1076
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 6
ER -